The MarketWatch News Department was not involved in the creation of this content. MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have ...
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please ...
Christos Soteriou was 29 when he needed a quadruple bypass surgery. Four arteries in his heart had become so clogged with plaque that blood could no longer flow through them. Subscribe to read this ...
April 2 (Reuters) - U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in ...
EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from ...
VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen ...
NEW ORLEANS—Adding the PCSK9 inhibitor evolocumab (Repatha; Amgen) to statin therapy significantly cuts the risk of major cardiovascular events when compared with statins alone in high-risk patients ...
Andy Coravos says offloading tedious tasks to AI has freed her to focus more on the things she loves, like singing and playing guitar. Andy Coravos has a new home helper—named Claude. She assigns her ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled, global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results